Drugs / Exendin-4Fc fusion protein
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06247748 | Oct 2023 → Apr 2024 | obesity disorder, type 2 diabetes mellitus | Beijing Dongfang Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06254014 | Jul 2024 → May 2026 overdue | type 2 diabetes mellitus | Beijing Dongfang Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exendin-4Fc fusion protein | “This study was designed as a multicenter, randomized, double-blind, placebo-parallel controlled Phase III clinical study to evaluate the efficacy and safety of Exendin-4Fc...” NCT06254014 ↗ |
| Known as | JY09 | “This study was designed as a multicenter, randomized, double-blind, placebo-parallel controlled Phase III clinical study to evaluate the efficacy and safety of Exendin-4Fc...” NCT06254014 ↗ |
| Modality | Protein / enzyme biologic | “Exendin-4Fc fusion protein” NCT06254014 ↗ |
| Route | Subcutaneous | “subcutaneous injection in the abdomen” NCT06254014 ↗ |